Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: committee papers
Table of contents:
1 Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
2 Consultee and commentator comments on the ACD from Janssen
3 Consultee and commentator comments on the ACD from PAPAA
4 Consultee and commentator comments on the ACD from Psoriasis Association
5 Consultee and commentator comments on the ACD from the Royal College of Nursing
6 Consultee and commentator comments on the ACD from AbbVie
Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: committee papers
12 March 2015 (1.02 Mb 2 sec) |
This page was last updated: 09 March 2015